A Study of the Effect of Terlipressin with Albumin Vs Only Albumin in Patients Diagnosed with Hepatorenal Syndrome (HRS)

Background: Hepatorenal syndrome (HRS) is a potentially reversible, functional renal failure that occurs in patients with advanced liver disease. HRS is generally characterized by increased serum creatinine, azotemia, reduced diuresis, increased urine osmolarity, and reduced urine sodium values without signs of organic kidney damage1. AIM: The aim of the study is to investigate the efficacy, adverse effects, and outcomes of Terlipressin with Albumin vs. only Albumin in patients diagnosed with hepatorenal syndrome. Material and methods: A single centred hospital-based descriptive ,observational study was conducted in patients admitted with a diagnosis of hepatorenal syndrome for 18 months (October 2019 to March 2021). A total 80 cases were studied. Results: All the parameters including Total Bilirubin, SGPT ( Serum glutamate pyruvate transaminase ), INR ( Internationalised normalised ratio ) and Serum Albumin were found to be similar ion both the groups except except SGOT (p=0.002) which was found to be significantly lower in Terlipressin +Albumin treatment group (61.89±47.83) compared to only albumin .(96.80±109.30). Those who were treated with Terlipressin +Albumin showed significant decrease in serum creatinine. A significant decrease in serum creatinine was observed at Day 5 (1.73±1.49) from Day 1 (3.47±1.68) making a mean percentage decrease of 50.14%